Sanofi GCVRZ 深 沪
等待开盘 09-24 09:30:00 美东时间
0.8711
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 0.8711
- 总市值 1113.52亿
- 52周最高 0.882
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 0.43
- 委 比 0.00%
- 总股本 1278.30亿
- 历史最高 0.882
- 量 比 0
- 振 幅 0.00%
- 历史最低 0.153
- 每 手 1
- 风险率 0.00%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多药物受理最新动态：Sanofi-Aventis Recherche & DéveloppementSAR448632注射用粉末进口申请获受理
国家药品监督管理局药品审评中心数据显示，2026年9月21日，Sanofi-Aventis Recherche & Développement的SAR...
09-21 19:15
RFK Jr. replaces federal autism panel chair: report
Pediatric neurologist John Gaitanis is the new chair of the Interagency Autism Coordinating Committee, replacing Sylvia Fogel, who had headed the panel since January. Gaitanis is also director of the...
09-19 04:56
药物受理最新动态：Sanofi B.V.注射用拉罗尼酶浓溶液补充申请获受理
国家药品监督管理局药品审评中心数据显示，2026年9月17日，Sanofi B.V.的注射用拉罗尼酶浓溶液申请已获受理，受理号为JYSB2600256。 ...
09-17 17:15
赛诺菲，转让3处生产基地565名员工
9月14日，赛诺菲（Sanofi）宣布拟与欧洲成熟药品领域领军企业Cheplapharm 达成合作。根据协议，Cheplapharm 将接手赛诺菲旗下 20 款...
09-15 17:21
Sanofi To Create Strategic Partnership With Cheplapharm; Cheplapharm Would Take Over From Sanofi A Selection Of 20 Mature Medicines And Three Manufacturing Sites Worldwide. In Return, Sanofi Will Receive A 26.4% Equity Stake In Cheplapharm
https://www.sanofi.com/en/media-room/press-releases/2026/2026-09-14-13-03-56-3361178
09-14 21:11
INmune Bio Appoints Sanofi Rare-Disease Executive and Biopharma Business Development Leader to Board
INmune Bio Inc. has appointed R. Duane Clark II and James Sapirstein to its Board of Directors to strengthen its commercialization planning and strategic partnering capabilities as Ebstrocel™ advances toward potential commercialization. Mr. Clark brings extensive experience in rare-disease commercialization, while Mr. Sapirstein adds expertise in business development and strategic transactions. These appointments aim to enhance market access, pri...
09-14 11:00
Scribe Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights
Scribe Therapeutics reported Q2 2026 financials and updates, including initiating the first-in-human Phase 1 trial for STX-1150, a novel LDL-C lowering therapy, and securing $25M in CIRM grants for STX-1200 and STX-1400 development. The company completed an upsized IPO, raising ~$155.5M, providing funding into 2029. Financial highlights include $43M cash as of June 2026 and a net loss of $6.5M for the quarter.
09-02 20:05
药物受理最新动态：SANOFI WINTHROP INDUSTRIE酒石酸唑吡坦片进口再注册申请获受理
国家药品监督管理局药品审评中心数据显示，2026年9月2日，SANOFI WINTHROP INDUSTRIE的酒石酸唑吡坦片申请已获受理，受理号为JYHZ2...
09-02 19:15
Scribe Therapeutics to Participate in Upcoming Investor Conferences
Scribe Therapeutics announced that its management will participate in three upcoming investor conferences: the Wells Fargo Healthcare Conference on Sept. 9, 2026, where CEO Benjamin Oakes will engage in a fireside chat; the H.C. Wainwright Global Investment Conference on Sept. 15, 2026, with Oakes presenting; and the Cell & Gene Meeting on the Mesa on Oct. 5, 2026, where CFO David Parrot will deliver an Innovation Spotlight presentation. Scribe T...
09-01 12:00
Sanofi Extends Lunsekimig COPD Program With Long-Term Safety Study
Sanofi SA ($SNY) announced an update on their ongoing clinical study. The study...
08-29 00:30
